This trial is designed to determine whether rapamycin is safe and effective treatment for patients with polycystic kidney disease (ADPKD). Patients will be followed by volumetric magnetic resonance imaging (MRI) to observe for change in kidney (and cyst) size. Blood and urine samples will also be collected to evaluate for change in biomarkers with treatment. ODM derived from:


Versions (1) ▾
  1. 4/4/19
Copyright Holder:
Yale University
Uploaded on:

April 4, 2019

No DOI assigned. To request one pleaselog in.
Creative Commons BY-NC 3.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease NCT00920309


  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
Exclusion Criteria